Melanoma & Skin Cancer

The hedgehog inhibitor sonidegib (Odomzo) showed continued antitumor activity with no new safety concerns in patients with advanced basal cell carcinoma.

The hedgehog inhibitor vismodegib (Erivedge) had an estimated disease control rate of 92.9% in the STEVIE trial, the largest ever study conducted in advanced basal cell carcinoma.

Antoni Ribas, MD, PhD, whose work has helped guide and define the growing array of anticancer immunotherapy drugs, was honored in the Melanoma category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

A new drug application has been submitted for binimetinib as a potential treatment for patients with advanced NRAS-mutant metastatic melanoma.

Reinhard Georg Dummer, MD, shares the encouraging phase III findings from the NEMO trial and how it shakes up the treatment paradigm for patients with NRAS-mutated melanoma.

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.

Morganna Freeman, DO, explains the impact of hedgehog inhibitors in basal cell carcinoma, the ideal patient to receive them, and emerging agents on the horizon for treatment of the disease.

Ryan J. Sullivan, MD, discusses which patients are at risk for advanced basal cell carcinoma, current standard therapies, and options for those who relapse after treatment with hedgehog/smoothened inhibitors.